CA2154161A1 - Therapeutic uses and delivery systems of dehydroepiandrosterone - Google Patents
Therapeutic uses and delivery systems of dehydroepiandrosteroneInfo
- Publication number
- CA2154161A1 CA2154161A1 CA002154161A CA2154161A CA2154161A1 CA 2154161 A1 CA2154161 A1 CA 2154161A1 CA 002154161 A CA002154161 A CA 002154161A CA 2154161 A CA2154161 A CA 2154161A CA 2154161 A1 CA2154161 A1 CA 2154161A1
- Authority
- CA
- Canada
- Prior art keywords
- precursors
- dehydroepiandrosterone
- treatment
- prevention
- sex steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 title abstract 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title abstract 2
- 229960002847 prasterone Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000002243 precursor Substances 0.000 abstract 4
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950009829 prasterone sulfate Drugs 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Abstract
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US561993A | 1993-01-19 | 1993-01-19 | |
US08/005,619 | 1993-01-19 | ||
US08/180,361 | 1994-01-18 | ||
US08/180,361 US5776923A (en) | 1993-01-19 | 1994-01-18 | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
PCT/CA1994/000022 WO1994016709A2 (en) | 1993-01-19 | 1994-01-19 | Therapeutic uses and delivery systems of dehydroepiandrosterone |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2154161A1 true CA2154161A1 (en) | 1994-08-04 |
CA2154161C CA2154161C (en) | 2006-12-12 |
Family
ID=21716809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002154161A Expired - Lifetime CA2154161C (en) | 1993-01-19 | 1994-01-19 | Therapeutic uses and delivery systems of dehydroepiandrosterone |
Country Status (10)
Country | Link |
---|---|
US (6) | US5776923A (en) |
EP (1) | EP1382340B1 (en) |
CN (3) | CN102357247A (en) |
CA (1) | CA2154161C (en) |
DK (1) | DK1382340T3 (en) |
IL (5) | IL181016A0 (en) |
MY (2) | MY134585A (en) |
SK (1) | SK286664B6 (en) |
UA (1) | UA73911C2 (en) |
ZA (1) | ZA94372B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021323A1 (en) * | 2007-08-10 | 2009-02-19 | Endorecherche, Inc. | Dhea compositions for treating menopause |
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
AU2012204083B2 (en) * | 2007-08-10 | 2014-10-09 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228852B1 (en) * | 1996-07-12 | 2001-05-08 | Carolyn V. Shaak | Transdermal application of naturally occurring steroid hormones |
US6117429A (en) * | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
TR200100063T2 (en) * | 1998-06-11 | 2001-05-21 | Endorecherche, Inc | Pharmaceutical compositions and uses for Androst-5-en-3ß, 17ß-diol |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
KR100302372B1 (en) * | 1998-07-24 | 2001-12-05 | 박상철 | Dihydroepiandrosterone derivatives for the prevention and treatment of osteoporosis |
US6726673B1 (en) * | 1999-05-24 | 2004-04-27 | Zars, Inc. | Methods and apparatus for improved administration of testosterone pharmaceuticals |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US7045513B1 (en) * | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
CN101543500A (en) | 1999-03-18 | 2009-09-30 | 基因实验室技术公司 | Dhea composition and method |
WO2000074684A1 (en) * | 1999-06-04 | 2000-12-14 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
EP1955700B9 (en) | 1999-09-30 | 2011-09-07 | Harbor BioSciences, Inc. | Therapeutic treatment of androgen receptor driven conditions |
FR2799645B1 (en) * | 1999-10-13 | 2004-04-30 | Oreal | USE OF DHEA OR ITS PRECURSORS OR METABOLIC DERIVATIVES AS DEPIGMENTANT |
US6846496B1 (en) | 1999-10-15 | 2005-01-25 | Orion Corporation | Treatment of osteoporosis |
US6605591B1 (en) | 1999-11-12 | 2003-08-12 | Genelabs Technologies, Inc. | Treatment of subnormal bone mineral density |
FR2803519B1 (en) * | 2000-01-12 | 2002-03-22 | Assist Publ Hopitaux De Paris | ORAL USE OF DEHYDROEPIANDROSTERONE, ITS PRECURSORS AND DERIVATIVES FOR IMPROVING THE PAPYRACE OF THE SKIN |
KR20020073566A (en) * | 2000-01-28 | 2002-09-27 | 앙도르쉐르슈 인코포레이티드 | Selective estrogen receptor modulators in combination with estrogens |
WO2001062259A1 (en) | 2000-02-25 | 2001-08-30 | Hollis Eden Pharmaceuticals | Method of treatment of prostate cancer |
FR2807323A1 (en) | 2000-04-10 | 2001-10-12 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING A STEROID AND A 2-ALKYL ALKANOL OR AN ESTER |
EP1289519B1 (en) | 2000-05-26 | 2019-02-13 | Harry Fisch | Methods of treating androgen deficiency in men using clomiphene |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
AU2001286995B2 (en) * | 2000-08-30 | 2006-11-30 | Besins Healthcare Luxembourg Sarl | Method for treating erectile dysfunction and increasing libido in men |
JP2004507511A (en) * | 2000-08-30 | 2004-03-11 | ユニメッド・ファーマシューティカルズ・インコーポレーテッド | Methods for increasing testosterone and related steroid levels in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
SI1347764T1 (en) * | 2000-12-22 | 2007-06-30 | August Wolff Gmbh & Co Kg Arzenmittel Dr | Gel composition based on alcohol for the treatment of hypogonadism through transscrotal application |
US20030119800A1 (en) * | 2001-06-18 | 2003-06-26 | Manolagas Stavros C. | Bone anabolic compounds and methods of use |
US7173064B2 (en) * | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
ES2312593T3 (en) * | 2001-07-09 | 2009-03-01 | Repros Therapeutics Inc. | PROCEDURES AND MATERIALS FOR THE TREATMENT OF THE DEFICIENCY OF TESTOSTERONE IN MEN. |
US7737185B2 (en) * | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
FR2827764B1 (en) * | 2001-07-27 | 2005-08-19 | Oreal | COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING A STEROID AND A GLYCOL |
FR2828100B1 (en) * | 2001-08-02 | 2004-09-24 | Galderma Res & Dev | REVERSE EMULSION COMPOSITION CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND ITS USE IN COSMETICS AND DERMATOLOGY |
EP1350541A1 (en) * | 2002-04-04 | 2003-10-08 | Jenapharm GmbH & Co. KG | Use of dehydroepiandrosterone and an estradiol derivative for preparing a medicament for treating postmenopausal climacteric disorders |
WO2003090754A1 (en) * | 2002-04-23 | 2003-11-06 | Sahltech I Göteborg AB | Use of dhea for treatment of female hypopituitarism |
KR100538386B1 (en) * | 2002-08-26 | 2005-12-27 | 메타볼랩(주) | A Pharmaceutical Composition for Treating IL-1 Related Diseases or Disorders |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
CA2501874A1 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
MXPA06003316A (en) | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues. |
US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
US20050239826A1 (en) * | 2004-04-14 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
WO2006019916A1 (en) * | 2004-07-14 | 2006-02-23 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
CA2595363C (en) * | 2005-02-04 | 2012-03-27 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
CA3071412A1 (en) * | 2005-03-22 | 2006-09-28 | Allergan Pharmaceuticals International Limited | Dosing regimes for trans-clomiphene |
EP2030622B1 (en) * | 2005-03-24 | 2011-02-23 | Emory University | Indication of dosage of progesterone in the treatment of a traumatic brain injury |
US7473687B2 (en) * | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
US20080058299A1 (en) * | 2005-04-12 | 2008-03-06 | Dudley Robert E | Method of treating or preventing bone deterioration or osteoporosis |
US8084446B2 (en) | 2005-04-26 | 2011-12-27 | Eric Marchewitz | Use of DHEA derivatives for enhancing physical performance |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
DK2450041T3 (en) | 2005-10-12 | 2018-11-19 | Unimed Pharmaceuticals Llc | Enhanced testosterone gel for use in the treatment of hypogonadism |
JP2009519926A (en) * | 2005-12-16 | 2009-05-21 | ライル コーポレート ディベロップメント インコーポレーテッド | Regeneration of vaginal tissue by non-systemic vaginal administration of estrogen |
CA2646667C (en) | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
CA2806526C (en) | 2007-10-16 | 2014-12-30 | Repros Therapeutics Inc. | Trans-clomiphen for type 2 diabetes |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
WO2013012430A1 (en) * | 2011-07-19 | 2013-01-24 | Riepl Michael S | Dhea bioadhesive controlled release gel |
UA113291C2 (en) | 2011-08-04 | 2017-01-10 | TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS | |
US9320744B2 (en) | 2011-10-19 | 2016-04-26 | Dhea Llc | DHEA bioadhesive controlled release gel |
WO2013098592A1 (en) | 2011-12-29 | 2013-07-04 | Universidad De Chile | Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause |
CN102631677A (en) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | Pharmaceutical composition for preventing and/or treating atherosclerosis |
JP2015535283A (en) | 2012-11-02 | 2015-12-10 | レプロス セラピューティクス インコーポレイティド | Trans-clomiphene for use in cancer therapy |
US20150313956A1 (en) * | 2014-05-05 | 2015-11-05 | Napier Consulting Llc | Compositions and methods for hair growth |
CN115554403B (en) * | 2022-08-16 | 2024-03-08 | 山东大学 | Use of the steroid hormone DHEA as receptor ADGRG2 agonist ligand |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK122125B (en) * | 1967-10-04 | 1972-01-24 | Schering Ag | Analogous process for the preparation of therapeutically active carboxylic acid esters of 3β-hydroxy-5-androstan-17-one (dehydroepiandrosterone) having 7-11 carbon atoms in the ester residue. |
US3551554A (en) * | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
JPS505372A (en) * | 1973-05-30 | 1975-01-21 | ||
US4006218A (en) * | 1974-07-08 | 1977-02-01 | Johnson & Johnson | Potentiated medicaments |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
DE2534911C2 (en) * | 1975-08-01 | 1985-04-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Process for the preparation of 5-androsten-17-one derivatives |
US4213978A (en) * | 1978-12-05 | 1980-07-22 | Interx Research Corporation | Anti-acne and anti-seborrhea prodrug derivatives of progesterone |
US4425339A (en) * | 1981-04-09 | 1984-01-10 | Syntex (U.S.A.) Inc. | Treatment of menopausal symptoms |
FR2518879A1 (en) * | 1981-12-30 | 1983-07-01 | Besins Jean | Topical oestradiol compsns. - for treatment of disorders associated with menopause |
US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
SE8303031D0 (en) * | 1983-05-30 | 1983-05-30 | Leo Ab | IMPROVED STEROID ESTERS PREPARATION |
US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
DE3333240A1 (en) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS |
US4725439A (en) * | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4812447A (en) * | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
NL194728C (en) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof. |
US4835147A (en) * | 1987-05-06 | 1989-05-30 | City Of Hope | Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction |
US5051260A (en) * | 1987-07-16 | 1991-09-24 | The Regents Of The University Of California | Method and composition for enhancing the cutaneous penetration of pharmacologically active agents |
US5064654A (en) * | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US5162037A (en) * | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US5047244A (en) * | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
WO1990006120A1 (en) * | 1988-12-01 | 1990-06-14 | Schering Corporation | Compositions for transdermal delivery of estradiol |
ES2077675T3 (en) * | 1989-03-10 | 1995-12-01 | Endorecherche Inc | COMBINED THERAPY FOR THE TREATMENT OF ESTROGEN SENSITIVE DISEASES. |
US4978532A (en) * | 1989-08-11 | 1990-12-18 | Pharmedic Co. | Dosage form for administration of dehydroepiandrosterone |
US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
US5071644A (en) * | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
HU222501B1 (en) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | Controlled release pharmaceutical composition containing mpa or mga and process for its preparation |
-
1994
- 1994-01-18 US US08/180,361 patent/US5776923A/en not_active Expired - Lifetime
- 1994-01-19 CA CA002154161A patent/CA2154161C/en not_active Expired - Lifetime
- 1994-01-19 IL IL181016A patent/IL181016A0/en unknown
- 1994-01-19 IL IL181018A patent/IL181018A/en not_active IP Right Cessation
- 1994-01-19 CN CN2011101909338A patent/CN102357247A/en active Pending
- 1994-01-19 MY MYPI94000149A patent/MY134585A/en unknown
- 1994-01-19 UA UA95073333A patent/UA73911C2/en unknown
- 1994-01-19 MY MYPI20064307A patent/MY157883A/en unknown
- 1994-01-19 IL IL181017A patent/IL181017A0/en unknown
- 1994-01-19 DK DK03019149T patent/DK1382340T3/en active
- 1994-01-19 CN CNA2008101680721A patent/CN101444519A/en active Pending
- 1994-01-19 ZA ZA94372A patent/ZA94372B/en unknown
- 1994-01-19 EP EP03019149A patent/EP1382340B1/en not_active Expired - Lifetime
- 1994-01-19 IL IL181015A patent/IL181015A/en not_active IP Right Cessation
- 1994-01-19 CN CNA2006100956345A patent/CN1954804A/en active Pending
- 1994-01-19 SK SK5103-2006A patent/SK286664B6/en not_active IP Right Cessation
- 1994-01-19 IL IL181019A patent/IL181019A0/en unknown
-
1995
- 1995-06-07 US US08/480,591 patent/US5728688A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,592 patent/US5824671A/en not_active Expired - Fee Related
- 1995-06-07 US US08/488,391 patent/US5922700A/en not_active Expired - Fee Related
- 1995-06-07 US US08/488,392 patent/US5780460A/en not_active Expired - Lifetime
-
1997
- 1997-11-13 US US08/969,197 patent/US5955455A/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
US10076525B2 (en) | 2004-10-20 | 2018-09-18 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women |
US10478443B2 (en) | 2004-10-20 | 2019-11-19 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women |
WO2009021323A1 (en) * | 2007-08-10 | 2009-02-19 | Endorecherche, Inc. | Dhea compositions for treating menopause |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
AU2008286651B2 (en) * | 2007-08-10 | 2012-11-22 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
US8629129B2 (en) | 2007-08-10 | 2014-01-14 | Endorecherche, Inc. | Pharmaceutical compositions |
AU2012204083B2 (en) * | 2007-08-10 | 2014-10-09 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
EA020683B1 (en) * | 2007-08-10 | 2015-01-30 | Эндорешерш, Инк. | Method for treating or reducing acquiring symptoms or diseases in postmenopausal women, intravaginal composition and suppository used therein |
AU2012204083C1 (en) * | 2007-08-10 | 2015-02-05 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
US8957054B2 (en) | 2007-08-10 | 2015-02-17 | Endorecherche, Inc. | Pharmaceutical compositions |
US10881650B2 (en) | 2007-08-10 | 2021-01-05 | Endorecherche, Inc. | Pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
DK1382340T3 (en) | 2006-08-14 |
SK286664B6 (en) | 2009-03-05 |
ZA94372B (en) | 1995-07-19 |
MY157883A (en) | 2016-08-01 |
MY134585A (en) | 2007-12-31 |
IL181018A (en) | 2012-07-31 |
IL181015A0 (en) | 2007-07-04 |
US5776923A (en) | 1998-07-07 |
IL181018A0 (en) | 2007-07-04 |
EP1382340B1 (en) | 2006-04-05 |
US5780460A (en) | 1998-07-14 |
US5955455A (en) | 1999-09-21 |
CA2154161C (en) | 2006-12-12 |
IL181016A0 (en) | 2007-07-04 |
IL181017A0 (en) | 2007-07-04 |
UA73911C2 (en) | 2005-10-17 |
US5728688A (en) | 1998-03-17 |
US5824671A (en) | 1998-10-20 |
CN101444519A (en) | 2009-06-03 |
IL181015A (en) | 2012-12-31 |
US5922700A (en) | 1999-07-13 |
CN1954804A (en) | 2007-05-02 |
IL181019A0 (en) | 2007-07-04 |
CN102357247A (en) | 2012-02-22 |
EP1382340A1 (en) | 2004-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2154161A1 (en) | Therapeutic uses and delivery systems of dehydroepiandrosterone | |
WO1994016709A3 (en) | Therapeutic uses and delivery systems of dehydroepiandrosterone | |
US4315925A (en) | Method of administering natural female sex hormones | |
US4383993A (en) | Nasal dosage forms containing natural female sex hormones | |
HU213408B (en) | Process for producing pharmaceutical compositions comprising drospirenon | |
HUP0102483A2 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
CA2391430A1 (en) | Improved transdermal contraceptive delivery system and process | |
Gompel et al. | Tibolone actions on normal and breast cancer cells | |
Ulmann | Uses of RU 486 for contragestion: an update | |
GB2138286A (en) | Pharmaceutical composition for the treatment of hair loss | |
Phillips | The selectivity of a new progestin | |
DE3339295A1 (en) | 4-Hydroxy- and 4-acyloxy-4-androstene-3,17-diones for use in the prophylaxis and therapy of prostate hyperplasia and compositions containing these for such a use | |
IE34308B1 (en) | 11beta,13beta dialkylgona-1,3,5(10)-trien-3-ol 3-cycloalkyl ethers | |
Dorfman et al. | The assay of orally administered androgens using the chick's comb | |
RU1789216C (en) | Composition showing contraceptive effect | |
ITBA920007A1 (en) | PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES | |
Dorfman et al. | Biosynthesis of steroids in various tissues related to feminizing syndromes | |
GB1244143A (en) | Trialkyl-silyloxy-steroids | |
KR20010102464A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140120 |